The record

We show our work.

Every claim in this library traces to a real study or a real FDA action. No vibes, no borrowed authority. Here they are — read them yourself.

Psilocybin

Twice named a Breakthrough Therapy by the FDA. In a head-to-head trial it matched a leading antidepressant and doubled its remission rate.

The FDA designated psilocybin therapy a Breakthrough Therapy for treatment-resistant depression.
FDA Breakthrough Therapy Designation — treatment-resistant depressionCOMPASS Pathways · U.S. Food and Drug Administration · 2018
Read the study
A second FDA Breakthrough Therapy designation followed, this one for major depressive disorder.
FDA Breakthrough Therapy Designation — major depressive disorderUsona Institute · U.S. Food and Drug Administration · 2019
Read the study
In a randomized trial against a leading SSRI, psilocybin matched it on the primary depression measure and produced twice the remission rate.
Trial of Psilocybin versus Escitalopram for DepressionCarhart-Harris R, et al. · New England Journal of Medicine · 2021
Read the study
In patients with life-threatening cancer, a single high dose produced large decreases in depression and anxiety — sustained at six months for about 80% of them.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancerGriffiths RR, et al. · Journal of Psychopharmacology · 2016
Read the study

The most advanced psychedelic trauma treatment cleared Phase 3.

In a randomized Phase 3 trial, MDMA-assisted therapy produced significant, lasting reductions in severe PTSD — safe and well-tolerated even in people with serious comorbidities.
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyMitchell JM, et al. · Nature Medicine · 2021
Read the study

One session has interrupted opioid dependence where everything else failed — and the newest research shows it repairing trauma in veterans.

In an observational study of opioid-dependent patients, 78% showed no objective withdrawal 48 hours after a single ibogaine treatment, with large reductions in craving.
Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomesBrown TK, Alper K. · The American Journal of Drug and Alcohol Abuse · 2018
Read the study
In 30 Special Operations veterans with traumatic brain injury, magnesium–ibogaine safely and substantially reduced PTSD, depression, anxiety, and disability.
Magnesium–ibogaine therapy in veterans with traumatic brain injuriesCherian KN, et al. · Nature Medicine · 2024
Read the study

The largest studies of people who actually microdose tell one story: less depression, less anxiety, less stress.

In the largest microdosing study to date — more than 8,000 people — those who microdosed, especially people managing mental-health concerns, reported lower depression, anxiety, and stress than those who did not.
Adults who microdose psychedelics report health-related motivations and lower levels of anxiety and depression compared to non-microdosersRootman JM, et al. · Scientific Reports · 2021
Read the study
Followed for a month against non-microdosing controls, psilocybin microdosers showed greater improvements in mood, depression, anxiety, and stress — with older microdosers also gaining in psychomotor performance.
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controlsRootman JM, et al. · Scientific Reports · 2022
Read the study
Tracking microdosers daily for six weeks, researchers measured real reductions in depression and stress, less distractibility, and greater absorption.
A systematic study of microdosing psychedelicsPolito V, Stevenson RJ. · PLOS ONE · 2019
Read the study

Updated 2026-07-27. A claim we can’t source doesn’t go on this page.